Moderna, Inc. (MRNA)
| Market Cap | 19.03B |
| Revenue (ttm) | 2.23B |
| Net Income (ttm) | -3.12B |
| Shares Out | 390.73M |
| EPS (ttm) | -8.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,929,517 |
| Open | 49.81 |
| Previous Close | 51.87 |
| Day's Range | 46.84 - 50.41 |
| 52-Week Range | 22.28 - 55.20 |
| Beta | 1.17 |
| Analysts | Hold |
| Price Target | 32.75 (-32.77%) |
| Earnings Date | Feb 13, 2026 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $32.75, which is a decrease of -32.77% from the latest price.
News
MRNY: Jumping On Big Moderna Move
YieldMax MRNA Option Income Strategy ETF has rebounded sharply from historic lows, driven by positive catalysts in underlying Moderna. MRNY's distributions have increased alongside MRNA's share price ...
Baseline characteristics in Moderna cancer vaccine 'misleading': Leerink's Dr. Mani Foroohar
Dr. Mani Foroohar, Leerink Partners, joins 'Closing Bell Overtime' to talk Moderna prices climbing on positive drug trial.
Moderna is curbing investment in vaccine trials due to US backlash
Moderna CEO Stephane Bancel said the company doesn't plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from US officials https://bloom.bg/3LNHufg
Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV
Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S. officials, CEO Stephane Bancel said in an interview with Bloomberg TV on Thurs...
MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off
Intel's (INTC) recent rally isn't the only one investors should pay attention to, says Diane King Hall. She points to Moderna (MRNA) hitting a 52-week high after a trial drug to treat melanoma posted ...
Moderna CEO Says Vaccine Scrutiny Is Curbing Trials
Moderna CEO Stephane Bancel says the company does not plan to invest in late-stage vaccine trials because of growing scrutiny of immunizations from US officials. He speaks with Lisa Abramowicz at the ...
MRNA Stock: Why 16% Pop May Signal More Upside
Moderna's stock, down 91% from its peak, jumped 16% on positive Phase 2b results for its mRNA skin cancer vaccine, showing a 49% reduction in recurrence.
What's Happening With Moderna Stock?
Moderna stock surged 16% yesterday after receiving promising clinical trial results for its experimental skin cancer vaccine. The firm is working on mRNA-1893/V940, a personalized cancer vaccine devel...
Moderna Stock Is Surging. Why a Cancer Vaccine Study Has Sparked a Rally.
Wall Street is hopeful that a pipeline of cancer drugs can drive earnings growth as the respiratory vaccine business flounders.
Stock Market Today: S&P 500, Dow Jones Futures Rise As Trump Scales Down EU Tariff Threats—Microsoft, Moderna, Intel In Focus
U.S. stock futures rose on Thursday following Wednesday's gains. Futures of major benchmark indices were higher.
Moderna, Merck Report Positive Results From Cancer-Vaccine Study
Moderna and Merck's cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.
Moderna, Merck's skin cancer vaccine shows sustained benefit after five years
Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, used in combination with Keytruda, reduced the risk of recurrence or death by 49% in a mid-stage trial.
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510;...
Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story
Moderna is undergoing a strategic shift, prioritizing infectious disease, oncology, and rare diseases to achieve cash break-even by 2028. 2026 is pivotal, with multiple oncology catalysts—especially I...
Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Moderna Stock Rises. Revenue in 2025 Will Be Higher Than Midpoint of Guidance.
Moderna also reiterates its expectations for revenue growth of up to 10% in 2026.
Moderna expects $1.9 billion in sales, trims costs forecast for 2025
Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its previously projected $1.6 billion to $2 billion forecast but well below reven...
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings Call Improves 2025 expected GAAP operating expenses by $200 million since 3Q25...
Moderna Stock Fights Back Against Four‑Year Curse With 20% Blastoff And A Golden Cross
Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ: MRNA) has quietly muscled its way into the top year-to-date performers, up more than 20% i...
America's new vaccine doctrine for children replaces data with dogma
In just a few weeks, the U.S. went from a “quiet” recalibration of a single vaccine recommendation to a wholesale retreat from the basic architecture of childhood immunization. That shift is being sol...
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an upda...
Moderna secures up to $54.3 million funding for bird flu vaccine from global coalition
Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S. drugmaker said on Thursday.
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threa...
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p...
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the...